非小细胞肺癌钻石突变靶向药,三代ALK掌控剂劳拉替尼价格(Lorlatinib)进军一线治疗
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">劳拉替尼(Lorlatinib)自<span style="color: black;">面世</span><span style="color: black;">败兴</span>就备受<span style="color: black;">喜爱</span>，这款三代靶向<span style="color: black;">药品</span>的强大之处在于<span style="color: black;">能够</span>克服所有已知的ALK抗性突变并可<span style="color: black;">经过</span>血脑屏障;可<span style="color: black;">控制</span>克唑替尼耐药的9种突变，对二代TKI<span style="color: black;">药品</span>耐药后仍有较高的有效性;<span style="color: black;">同期</span>劳拉替尼<span style="color: black;">亦</span><span style="color: black;">拥有</span>较强的血脑屏障透过能力，入脑效果较强，<span style="color: black;">尤其</span>适合对其他ALK耐药的晚期NSCLC<span style="color: black;">病人</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 1.针对<span style="color: black;">区别</span>类型的ALK+<span style="color: black;">病人</span>，一线<span style="color: black;">运用</span>，<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>率最高达90%;</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 2.更<span style="color: black;">要紧</span>的是，<span style="color: black;">针对</span>克唑替尼耐药的<span style="color: black;">病人</span><span style="color: black;">来讲</span>，继续<span style="color: black;">运用</span>Lorlatinib，<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>率69%;</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 3.而<span style="color: black;">针对</span>三种ALK<span style="color: black;">控制</span>剂都耐药的<span style="color: black;">病人</span>，Lorlatinib<span style="color: black;">亦</span>有很好的效果，<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>率高达39%。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">因此呢</span>劳拉替尼既往<span style="color: black;">做为</span>最后的保底药物，对其他ALK<span style="color: black;">控制</span>剂耐药仍有效。此前的NCCN指南将劳拉替尼列为三线保底治疗<span style="color: black;">举荐</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> 此次CROWN<span style="color: black;">科研</span>的<span style="color: black;">要紧</span>结果为其由三线保底<span style="color: black;">药品</span>逆袭为一线首选治疗奠定了<span style="color: black;">基本</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CROWN是一项专门对比克唑替尼和劳拉替尼一线治疗ALK阳性非小细胞肺癌临床效果的3期临床<span style="color: black;">科研</span>，其中296名先前未经治疗的晚期ALK阳性NSCLC<span style="color: black;">病人</span>被1:1随机分为接受劳拉替尼单药治疗或克唑替尼单药治疗，<span style="color: black;">重点</span>审查两组<span style="color: black;">药品</span>的中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期(PFS)，其次<span style="color: black;">包含</span>总体<span style="color: black;">存活</span>率、反应<span style="color: black;">连续</span>时间(DR)以及安全性等，让<span style="color: black;">咱们</span><span style="color: black;">一起</span>期待即将<span style="color: black;">颁布</span>的<span style="color: black;">最后</span>结果。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">将来</span>已来!ALK阳性肺癌<span style="color: black;">病人</span>迎来<span style="color: black;">更加多</span>续命好药</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">大约3~13的非小细胞肺癌<span style="color: black;">病人</span><span style="color: black;">显现</span>ALK重排，化疗的客观缓解率仅为45%，这<span style="color: black;">寓意</span>化疗仅对不到一半的<span style="color: black;">病人</span><span style="color: black;">生效</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">十年前，<span style="color: black;">第1</span>款针对ALK重排的<span style="color: black;">控制</span>剂<span style="color: black;">面世</span>，将客观缓解率<span style="color: black;">提高</span>至74%，为<span style="color: black;">病人</span><span style="color: black;">明显</span><span style="color: black;">增多</span>了治疗机会。在不到十年的时间里，非小细胞肺癌的ALK突变<span style="color: black;">已然</span>从一个几乎不<span style="color: black;">认识</span>的<span style="color: black;">行业</span>发展越来越清晰，尽管针对这一靶点的<span style="color: black;">药品</span>不如EGFR等靶点的靶向<span style="color: black;">药品</span>数量多，但整体<span style="color: black;">来讲</span>，疗效都<span style="color: black;">非常</span>惊艳。<span style="color: black;">日前</span>已<span style="color: black;">获准</span>的五款ALK-TKI<span style="color: black;">药品</span>中，最早<span style="color: black;">获准</span>的克唑替尼能将ALK阳性非小细胞肺癌<span style="color: black;">病人</span>的中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期延长近5个月，布加替尼治疗的中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期达到13.8个月，赛瑞替尼达到16.6个月，阿来替尼<span style="color: black;">更加是</span>达到了惊人的34.8个月，<span style="color: black;">作为</span>ALK重排NSCLC一线治疗的首选<span style="color: black;">药品</span>!</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">劳拉替尼是第三代ALK / ROS1<span style="color: black;">控制</span>剂，与克唑替尼相比，劳拉替尼对野生型EML4-ALK的效力约高10倍，对EML4-ALK L1196M的效力约高40倍。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">除此之外，我国<span style="color: black;">针对</span>ALK-TKI的<span style="color: black;">科研</span><span style="color: black;">亦</span>紧跟国际步伐，靶向新药展现出非凡的<span style="color: black;">潜能</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在2020年世界肺癌大会上，<span style="color: black;">科研</span>者公开了二代国产ALK-TKI<span style="color: black;">药品</span>恩沙替尼(Ensartinib)的临床<span style="color: black;">实验</span>数据，<span style="color: black;">做为</span>一线治疗，将ALK阳性非小细胞肺癌<span style="color: black;">病人</span>的<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期推进到了25.8个月，<span style="color: black;">明显</span>超过了一代ALK-TKI<span style="color: black;">药品</span>克唑替尼的12.7个月。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">另一</span>国内药企自主<span style="color: black;">开发</span>的二代ALK-TKI<span style="color: black;">药品</span>CT-707治疗非小细胞肺癌的Ⅰ期临床<span style="color: black;">实验</span><span style="color: black;">亦</span>在北京协和医院进行中，共招募13位<span style="color: black;">病人</span>，其结果<span style="color: black;">表示</span>，CT-707一线治疗ALK阳性晚期非小细胞肺癌<span style="color: black;">病人</span>，450 mg q.d剂量组的客观缓解率为87.5%，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率达到了100%;<span style="color: black;">针对</span>克唑替尼耐药的<span style="color: black;">病人</span>，300 mg b.i.d剂量组的客观缓解率为83.3%，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率达到100%，疗效在同类<span style="color: black;">药品</span>中表现优异;在<span style="color: black;">每日</span><span style="color: black;">最少</span>接受450 mg CT-707治疗的12例肺腺癌<span style="color: black;">病人</span>中，58%的<span style="color: black;">病人</span>治疗<span style="color: black;">连续</span>时间为11个月或更<span style="color: black;">长期</span>，中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为13个月。</p>
楼主果然英明！不得不赞美你一下！ 楼主的文章深得我心，表示由衷的感谢！ 谷歌网站排名优化 http://www.fok120.com/
页:
[1]